Wall Street Zen upgraded shares of CalciMedica (NASDAQ:CALC – Free Report) to a sell rating in a research report report published on Saturday.
A number of other research analysts also recently issued reports on CALC. Weiss Ratings downgraded CalciMedica from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 13th. UBS Group reaffirmed a “neutral” rating on shares of CalciMedica in a research note on Thursday, August 13th. HC Wainwright reaffirmed a “neutral” rating on shares of CalciMedica in a report on Wednesday, July 29th. Finally, Guggenheim began coverage on shares of CalciMedica in a research note on Thursday. They issued a “buy” rating for the company. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, CalciMedica presently has an average rating of “Hold” and a consensus target price of $10.00.
Check Out Our Latest Analysis on CalciMedica
CalciMedica Price Performance
CalciMedica (NASDAQ:CALC – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.17). Research analysts predict that CalciMedica will post -1.05 earnings per share for the current year.
Insider Transactions at CalciMedica
In other CalciMedica news, Director Fred A. Middleton acquired 248,972 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were bought at an average cost of $0.80 per share, with a total value of $199,177.60. Following the completion of the acquisition, the director owned 1,063,272 shares in the company, valued at approximately $850,617.60. This trade represents a 30.57% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 28.25% of the company’s stock.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the business. 180 Wealth Advisors LLC lifted its holdings in CalciMedica by 297.2% during the first quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock valued at $68,000 after purchasing an additional 94,650 shares in the last quarter. Boothbay Fund Management LLC purchased a new stake in shares of CalciMedica during the fourth quarter worth about $506,000. PVG Asset Management Corp acquired a new position in shares of CalciMedica during the 4th quarter worth about $302,000. Renaissance Technologies LLC raised its position in shares of CalciMedica by 45.0% during the 1st quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after purchasing an additional 39,775 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its position in shares of CalciMedica by 58.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after purchasing an additional 34,386 shares during the last quarter.
CalciMedica Company Profile
CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.
The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.
Featured Stories
- Five stocks we like better than CalciMedica
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.
